Efficacy and safety of ABT-874, a monoclonal anti–interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial

✍ Scribed by Alexa B. Kimball; Kenneth B. Gordon; Richard G. Langley; Alan Menter; Renee J. Perdok; Joaquin Valdes

• Book ID: 116586716
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 620 KB
• Volume: 64
• Category: Article
• ISSN: 1097-6787
• DOI: 10.1016/j.jaad.2010.01.030